Literature DB >> 10225907

Humoral immune responses to Neisseria meningitidis in children.

A J Pollard1, R Galassini, E M van der Voort, R Booy, P Langford, S Nadel, C Ison, J S Kroll, J Poolman, M Levin.   

Abstract

An understanding of the nature of immunity to serogroup B meningococci in childhood is necessary in order to establish the reasons for poor responses to candidate vaccines in infancy. We sought to examine the nature of humoral immune responses following infection in relation to age. Serum bactericidal activity was poor in children under 12 months of age despite recent infection with Neisseria meningitidis. The highest levels of bactericidal activity were seen in children over 10 years of age. However, infants produced levels of total immunoglobulin G (IgG) and IgG subclass antibodies similar to those in older children in a meningococcal enzyme-linked immunosorbent assay. Most antibody was of the IgG1 and IgG3 subclasses. This striking age dependency of bactericidal antibody response following infection is not apparently due to failure of class switching in infants but might be due to qualitative differences in antibody specificity or affinity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225907      PMCID: PMC115990          DOI: 10.1128/IAI.67.5.2441-2451.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  Point mutation in meningococcal por A gene associated with increased endemic disease.

Authors:  B T McGuinness; I N Clarke; P R Lambden; A K Barlow; J T Poolman; D M Jones; J E Heckels
Journal:  Lancet       Date:  1991-03-02       Impact factor: 79.321

2.  Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis.

Authors:  D L Kasper; J L Winkelhake; B L Brandt; M S Artenstein
Journal:  J Infect Dis       Date:  1973-04       Impact factor: 5.226

3.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

4.  Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants.

Authors:  R E Mandrell; W D Zollinger
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

5.  Recurrent meningococcemia associated with IgG2-subclass deficiency.

Authors:  J L Bass; R Nuss; K A Mehta; P Morganelli; L Bennett
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

6.  Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis.

Authors:  L Skevakis; C E Frasch; J M Zahradnik; R Dolin
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

7.  Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity.

Authors:  A Nicholson; I H Lepow
Journal:  Science       Date:  1979-07-20       Impact factor: 47.728

8.  Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.

Authors:  W D Zollinger; R E Mandrell
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

9.  Human immunity to the meningococcus. II. Development of natural immunity.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  15 in total

1.  Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.

Authors:  K T Mountzouros; A P Howell
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Improved method to calculate the antibody avidity index.

Authors:  C T Perciani; P S Peixoto; W O Dias; F S Kubrusly; M M Tanizaki
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

3.  Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides.

Authors:  Richarda M de Voer; Fiona R M van der Klis; Carla W A M Engels; Ger T Rijkers; Elisabeth A Sanders; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2008-06-11

4.  Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles.

Authors:  M J Hopkins; R Sharp; G T Macfarlane
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

5.  A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.

Authors:  R Abad; A Biolchi; M Moschioni; M M Giuliani; M Pizza; J A Vázquez
Journal:  Clin Vaccine Immunol       Date:  2015-01-28

6.  Neisserial immunoglobulin A1 protease induces specific T-cell responses in humans.

Authors:  Anastasios Tsirpouchtsidis; Robert Hurwitz; Volker Brinkmann; Thomas F Meyer; Gaby Haas
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

7.  Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

Authors:  N Ruijne; R A Lea; J O'Hallahan; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2006-07

8.  Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis.

Authors:  J Wang; G A Jarvis; M Achtman; E Rosenqvist; T E Michaelsen; A Aase; J M Griffiss
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

9.  Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Tsegaye Alebel; Degu Berhanu; Morten Harboe; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

Review 10.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.